BioSpace News Archive

Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), today announced that James Lanthier, CEO, and Joseph Araujo, CSO of Mindset, will participate in the H.C. Wainwright 24th Annual Global Investment Conference to be held at the Lotte New York Palace Hotel in New York City on September 12-14, 2022.

Bioventus Inc., a global leader in innovations for active healing, announced that Mark Singleton, senior vice-president and chief financial officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Wednesday, September 14, 2022, at 11:10 a.m. ET.

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported top line data from the randomized Phase 2 SELECT trial evaluating vopratelimab (vopra).

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number 7116547) entitled “Combined Preparations for the Treatment of Cancer or Infection” by the Japanese Patent Office.

Genetic Technologies Limited, a global leader in guideline driven genomics-based tests in health, wellness and serious disease is pleased to report annual results for the year ended June 30, 2022.

Aristea Therapeutics today announced the dosing of the first patient in its Phase 2a trial evaluating RIST4721, a CXCR2 antagonist, for the treatment of hidradenitis suppurativa (HS).

Seelos Therapeutics, Inc. today announced that it will participate in two upcoming psychedelic conferences.

Cybin Inc. is pleased to announce that the first two participants have been dosed in its Phase 1/2a trial evaluating CYB003 for the treatment of major depressive disorder.

Parse Biosciences announced today a significant performance update of its chemistry for the Evercode™ Whole Transcriptome products.

LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, convened a team of oncology thought leaders, the United States Food and Drug Administration, the National Cancer Institute, and industry sponsors to develop recommendations for a framework for lung cancer clinical trial eligibility criteria.